![]() ![]() The trial lasted from April 30 to May 17 in Harford Superior Court in Connecticut, where about 3,000 similar Pradaxa lawsuits are currently pending and awaiting trial. However, the lawsuit claimed the manufacturer failed to warn users and the medical community that GERD placed patients at an increased risk of bleeding problems. Roberto had a 40-year history of gastroesophageal reflux disease (GERD), which his lawsuit indicated put him at a higher risk of bleeding events when taking Pradaxa. As a result of the bleeding injury, he was hospitalized for 10 days and underwent months of recovery. The court will now determine the amount of punitive damages during an upcoming hearing, which may be up to two times the amount of the compensatory damages award.Īfter using Pradaxa, Roberto indicated that he suffered a life-threatening upper gastrointestinal bleeding event on January 30, 2014. The verdict was handed down on Friday, in a Pradaxa lawsuit filed by Eugene Roberto, including $42,645 for past medical expenses and $500,000 for non-economic damages, such as pain and suffering. Start your single-user one-year subscription (250 issues) FDAnews for only $1,895.Īlso available: Take advantage of our multi-user and site licenses of FDAnews, so you’ll have the most-informed workforce! Contact Will Tuttle, Business Development Representative at or +1 612.216.2948 to receive a custom quote.A Connecticut jury has determined that Boehringer Ingelheim should pay more than half a million dollars in compensatory damages to a New York man who suffered a severe bleeding injury from Pradaxa, and that additional punitive damages should be awarded to punish the drug maker for failing to adequately warn consumers and the medical community about the risks associated with the controversial anticoagulant. Start your subscription to FDAnews - the trusted source for drug and device insights - today. It makes sense of everything successful drug and device manufacturers must know and do, delivering the news, analysis and interpretation of industry changes you need to stay in compliance and thrive. ![]() Daily posts of breaking headlines and premium stories throughout the day on įDAnews delivers precisely what you need to know each business day.Excerpts of best-selling FDAnews webinar and book content.Original columns from thought leaders and former FDA officials on trending topics.In-depth exposés that take a deep dive into essential pharmaceutical and device issues.Reports and perspective on Form 483s, warning letters, recalls, FDA policy notices and other reports.Global enforcement and supply chain trends.FDA inspection policies, practices and enforcement activities.Quality and GMP regulatory policies and developments.FDA budgets and spending, including proposals and approvals by Congress and the President.Company mergers and technology developments.Draft and final guidances from the FDA and other regulatory agencies.Best practices in regulatory compliance and the pathways to approval.Written and reported by FDAnews’ team of experienced industry journalists and subject matter experts, each issue delivers coverage of the regulatory, legislative and business changes affecting the global drug and device industry.Įach business day, FDAnews provides valuable insights into: FDAnews delivers what you need to know each business day. These two publications have recently merged to become FDAnews, a trusted one-stop destination for drug and device insights. The trusted source for drug and device insightsĬompliance - and business success - are rooted in an understanding of the top pharma, medical device and regulatory developments.įor decades, top drug and device manufacturers have relied on FDAnews’ insightful coverage with two of the industry’s most-trusted publications: Drug Industry Daily and Device Daily Bulletin Premium. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |